PDT Partners LLC bought a new position in Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 37,718 shares of the insurance provider's stock, valued at approximately $14,982,000. Humana comprises 0.8% of PDT Partners LLC's portfolio, making the stock its 20th biggest position.
A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Humana by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider's stock valued at $3,652,890,000 after purchasing an additional 106,030 shares during the last quarter. BlackRock Inc. bought a new stake in Humana in the second quarter worth about $4,138,160,000. Capital International Investors lifted its stake in Humana by 113.9% in the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock worth $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. Pzena Investment Management LLC boosted its position in shares of Humana by 34.3% during the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider's stock valued at $948,614,000 after buying an additional 1,398,774 shares during the period. Finally, State Street Corp boosted its position in shares of Humana by 1.8% during the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider's stock valued at $1,403,877,000 after buying an additional 97,211 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Trading Up 0.6%
HUM opened at $388.92 on Wednesday. The stock's fifty day moving average is $383.88 and its two-hundred day moving average is $285.00. The company has a market capitalization of $46.70 billion, a P/E ratio of 36.79, a PEG ratio of 2.20 and a beta of 0.72. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $428.88. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62.
Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. During the same period in the prior year, the business earned $6.27 EPS. The business's revenue for the quarter was up 26.2% compared to the same quarter last year. Analysts forecast that Humana Inc. will post 9.12 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on HUM shares. Zacks Research downgraded Humana from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Cantor Fitzgerald upped their price objective on Humana from $264.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, July 7th. Needham & Company LLC began coverage on Humana in a research note on Wednesday, May 20th. They issued a "buy" rating on the stock. TD Cowen boosted their target price on shares of Humana from $350.00 to $370.00 and gave the company a "hold" rating in a research note on Friday, July 31st. Finally, Robert W. Baird set a $390.00 target price on shares of Humana in a research note on Thursday, July 30th. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $403.91.
Get Our Latest Stock Report on Humana
Humana Company Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
